Effective treatment of severe COVID-19 patients with tocilizumab

Xiaoling Xu,Mingfeng Han,Tiantian Li,Wei Sun,Dongsheng Wang,Binqing Fu,Yonggang Zhou,Xiaohu Zheng,Yun Yang,Xiuyong Li,Xiaohua Zhang,Aijun Pan,Haiming Wei
DOI: https://doi.org/10.1073/pnas.2005615117
IF: 11.1
2020-04-29
Proceedings of the National Academy of Sciences
Abstract:Significance In patients with coronavirus disease 2019, a large number of T lymphocytes and mononuclear macrophages are activated, producing cytokines such as interleukin-6 (IL-6), which bind to the IL-6 receptor on the target cells, causing the cytokine storm and severe inflammatory responses in lungs and other tissues and organs. Tocilizumab, as a recombinant humanized anti-human IL-6 receptor monoclonal antibody, can bind to the IL-6 receptor with high affinity, thus preventing IL-6 itself from binding to its receptor, rendering it incapable of immune damage to target cells, and alleviating the inflammatory responses.
multidisciplinary sciences
What problem does this paper attempt to address?